Loading...
XSHE002332
Market cap1.32bUSD
Jan 15, Last price  
9.70CNY
1D
1.97%
1Q
-22.68%
Jan 2017
14.45%
IPO
19.90%
Name

Zhejiang Xianju Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002332 chart
P/E
17.04
P/S
2.33
EPS
0.57
Div Yield, %
3.12%
Shrs. gr., 5y
1.58%
Rev. gr., 5y
2.63%
Revenues
4.12b
-5.85%
765,330,681966,789,3371,133,516,5221,276,721,0341,500,980,9331,689,209,5981,992,191,5442,315,040,5652,470,533,0192,480,246,1532,503,730,3452,852,555,2623,621,754,7133,708,545,5304,018,872,7724,337,150,9644,379,825,6954,123,418,584
Net income
563m
-24.86%
49,529,72464,636,46165,037,69988,841,792120,165,635132,869,614120,557,25460,591,46856,695,716106,551,038146,186,888206,630,126301,362,969410,368,585504,509,427619,325,646749,411,381563,083,493
CFO
595m
-2.27%
53,052,17996,534,59036,030,822104,678,023155,292,369147,627,79833,427,87163,461,725141,638,736199,607,086155,905,554167,466,085193,266,995519,805,113789,233,376676,151,765609,284,602595,482,358
Dividend
Jun 05, 20240.3 CNY/sh
Earnings
May 21, 2025

Profile

Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. The company offers active pharmaceutical ingredients, such as steroid drugs, and male and female hormones; intermediates; and finished formulations in the form of tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-injections. Zhejiang Xianju Pharmaceutical Co.,Ltd. was founded in 1972 and is based in Xianju, China.
URL
http://www.xjpharma.com/
IPO date
Jan 12, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,123,419
-5.85%
4,379,826
0.98%
Cost of revenue
3,163,426
3,457,615
Unusual Expense (Income)
NOPBT
959,993
922,210
NOPBT Margin
23.28%
21.06%
Operating Taxes
79,562
124,506
Tax Rate
8.29%
13.50%
NOPAT
880,431
797,704
Net income
563,083
-24.86%
749,411
21.00%
Dividends
(299,766)
(148,381)
Dividend yield
2.38%
1.33%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
167,395
146,162
Long-term debt
58,249
202,658
Deferred revenue
57,857
54,526
Other long-term liabilities
9,528
8,485
Net debt
(1,730,858)
(1,672,648)
Cash flow
Cash from operating activities
595,482
609,285
CAPEX
(234,632)
Cash from investing activities
(199,630)
358,066
Cash from financing activities
(463,847)
FCF
671,403
696,358
Balance
Cash
1,660,044
1,720,466
Long term investments
296,458
301,002
Excess cash
1,750,331
1,802,477
Stockholders' equity
3,580,903
3,780,907
Invested Capital
4,362,990
4,056,021
ROIC
20.92%
19.59%
ROCE
15.70%
15.74%
EV
Common stock shares outstanding
987,866
989,205
Price
12.77
13.01%
11.30
-14.39%
Market cap
12,615,046
12.86%
11,178,015
-14.39%
EV
10,928,113
9,555,360
EBITDA
1,180,081
1,115,210
EV/EBITDA
9.26
8.57
Interest
6,641
6,288
Interest/NOPBT
0.69%
0.68%